曾和松,颜红兵,余小平

• 1:华中科技大学同济医学院附属同济医院心血管内科
• 2:国家心血管病中心北京协和医学院中国医学科学院阜外医院冠心病中心
• 3:国家心血管病中心中国医学科学院阜外医院深圳医院冠心病中心

摘要(Abstract)：

<正>阿司匹林联合氯吡格雷双联抗血小板治疗(dual antiplatelettherapy,DAPT)是接受经皮冠状动脉介入治疗(percutaneous coronary intervention, PCI)患者术后的标准治疗[1-2]。氯吡格雷仍然是目前使用最广泛的P2Y12抑制药[3]。然而,由于基因变异,大约三分之一的患者对氯吡格雷无或低反应,需要接受新型P2Y12抑制药治疗(例如替格瑞洛或普拉格雷)[4-5]。因此,如何根据基因类型量身定制抗血小板治疗方案一直是临床研究的热点[6-7]。

关键词(KeyWords)： 基因分型;抗血小板治疗

Abstract:

Keywords:

基金项目(Foundation):

作者(Author): 曾和松,颜红兵,余小平

参考文献(References)：

• [1]Levine GN,Bates ER,Bittl JA,et al.2016 ACC/AHA guideline focused update on duration of dual antiplatelet therapy in patients with coronary artery disease:a report of the American College of Cardiology/American Heart Association task force on Clinical Practice Guidelines.J Am Coll Cardiol,2016,68(10):1082-1115.
• [2]Valgimigli M,Bueno H,Byrne RA,et al.2017 ESC focused update on dual antiplatelet therapy in coronary artery disease developed in collaboration with EACTS:The task force for dual antiplatelet therapy in coronary artery disease of the European Socieyt of Cardiology(ESC)and of the European Association for CardioThoracic Surgery(EACTS).Eur Heart J,2018,39(3):213-260.
• [3]Khalid U,Bandeali S,Jones PG,et al.Prescription patterns of clopidogrel,prasugrel and ticagrelor after percutaneous coronary intervention with stent implantation(from the NCDR PINNACLERegistry).Am J Cardiol,2019,124(12):1807-1812.
• [4]Parodi G,Marcucci R,Valenti R,et al.High residual platelet reactivity after clopidogrel loading and long-term cardiovascular events among patients with acute coronary syndromes undergoing PCI.JAMA,2011,306(11):1215-1223.
• [5]Oliphant CS,Trevarrow BJ,Dobesh PP.Clopidogrel response variability:review of the literature and practical considerations.J Pharm Pract,2016,29(1):26-34.
• [6]Sibbing D,Aradi D,Alexopoulos D,et al.Updated expert consensus statement on platelet function and genetic testing for guiding P2Y12receptor inhibitor treatment in percutaneous coronary intervention.JACCCardiovasc Interv,2019,12(16):1521-1537.
• [7]Angiolillo DJ,Capodanno D,Danchin N,et al.Derivation,validation,and prognostic utility of a prediction rule for nonresponse to clopidogrel:the ABCD-GENE Score.J Am Coll Cardiol Intv,2020,13(5):606-617.
• [8]Naveen L.Tailored antiplatelet initiation to lessen outcomes due to decreased clopidogrel response after percutaneous coronary intervention-TAILOR PCI.March 28,2020.https：//www.acc.org/latest-in-cardiology/clinical-trials/2020/03/26/19/53/tailor-pci
• [9]Taubert D,von Beckerath N,Grimberg G,et al.Impact of P-glycoprotein on clopidogrel absorption.Clin Pharmacol Ther,2006,80(5):486-501.
• [10]Farid NA,Kurihara A,Wrighton SA.Metabolism and disposition of the thienopyridine antiplatelet drugs ticlopidine,clopidogrel,and prasugrel in humans.J Clin Pharmacol,2010,50(2):126-142.
• [11]Hollopeter G,Jantzen HM,Vincent D,et al.Identifi cation of the platelet ADP receptor targeted by antithrombotic drugs.Nature,2001,409(6817):202-207.
• [12]Kazui M,Nishiya Y,Ishizuka T,et al.Identifi cation of the human cytochrome P450 enzymes involved in the two oxidative steps in the bioactivation of clopidogrel to its pharmacologically active metabolite.Drug Metab Dispos,2010,38(1):92-99.
• [13]Price MJ,Angiolillo DJ.Pharmacogenomic testing to select antiplatelet therapy.J Am Coll Cardiol,2018,71(17):1878-1881.
• [14]Mega JL,Close SL,Wiviott SD,et al.Cytochrome p-450polymorphisms and response to clopidogrel.N Engl J Med,2009,360(4):354-362.
• [15]Simon T,Verstuyft C,Mary-Krause M,et al.Genetic determinants of response to clopidogrel and cardiovascular events.N Engl J Med,2009,360(4):363-375.
• [16]Mega JL,Simon T,Collet JP,et al.Reduced-function CYP2C19genotype and risk of adverse clinical outcomes among patients treated with clopidogrel predominantly for PCI:a meta-analysis.JAMA,2010,304(16):1821-1830.
• [17]Holmes MV,Perel P,Shah T,et al.CYP2C19 genotype,clopidogrel metabolism,platelet f unction,and cardiovascular events:a systematic review and meta-analysis.JAMA,2011,306(24):2704-2714.
• [18]Holmes DR Jr,Dehmer GJ,Kaul S,et al.ACCF/AHA clopidogrel clinical alert:approaches to the FDA“boxed warning”:a report of the American College of Cardiology Foundation task force on clinical expert consensus documents and the American Heart Association endorsed by the Soeiety for Cardiovascalar Angiography and Interventions and the Society of Thoracic Surgeons.J Am Coll Cardiol,2010,56(4):321-341.
• [19]Scott SA,Sangkuhl K,Stein CM,et al.Clinical Pharmacogenetics Implementation Consortium guidelines for CYP2C19 genotype and clopidogrel therapy:2013 update.Clin Pharmacol Ther,2013,94(3):328-332.
• [20]Cavallari LH,Lee CR,Beitelshees AL,et al.Multisite investigation of outcomes with implementation of CYP2C19 genotype-guided antiplatelet therapy after percutaneous coronary intervention.JACCCardiovasc Interv,2018,11(2):181-191.
• [21]Lee CR,Sriramoju VB,Cervantes A,et al.Clinical outcomes and sustainability of using CYP2C19 genotype-guided antiplatelet therapy after percutaneous coronary intervention.Circ Genom Precis Med,2018,11(4):e002069
• [22]Claassens DMF,Vos GJA,Bergmeijer TO,et al.A genotypeguided strategy for oral P2Y12 inhibitors in primary PCI.N Engl JMed,2019,381(17):1621-1631.